Growth & Returns

A new wave of advanced cancer drugs is set to upend the market. As the EGFR inhibitor space surges towards $16B, we analyze the strategies behind the disruption.

As Netflix preps its Q2 2026 report, investors look past subscriber numbers to the real story: the success of its ad-supported tiers and gaming bets.

The online therapy market is booming, attracting institutional capital. We dissect the growth drivers, regulatory risks, and evolving business models.

New data reveals a startling truth: confusing parking payments aren't just annoying—they're costing local businesses and reshaping how we live in our cities.

Restore Hyper Wellness is using a gamified challenge to keep clients engaged this summer. But is this a new frontier in personal resilience or just savvy marketing?

With its 'Fan House' pop-up, SharkNinja and Amazon Ads are rewriting the retail playbook, proving that the best shopping cart is a lived experience.

T. Rowe Price appoints 20-year veteran Mike Barry as marketing chief, signaling a major push into AI and digital to drive global growth and client engagement.

With 500,000 voters at risk of being silenced, Élections Québec is overhauling its process. Here's how they're making every vote count in 2026.

While a local Indiana story highlights the human cost of caregiver burnout, it unveils a massive, underserved market poised for explosive growth and fintech innovation.

New data reveals elevated cortisol in over 75% of hard-to-treat diabetes patients, paving the way for a novel drug to tackle treatment resistance.

A small Houston firm's modular waste-to-methanol plant in Porto is more than a green project; it's a strategic blueprint for European energy sovereignty.

Clip Money extends its debt runway, but a split among investors reveals a deeper story. Is this a savvy move to fuel expansion or a necessary patch on a leaky hull?

Legend Biotech's stunning trial results for an 'in vivo' CAR-T therapy could make advanced cancer treatment faster, safer, and accessible to all.

With CEO Reedy's sudden retirement, aerospace innovator Butler National enters a critical transition. We explore his legacy and what's next for the tech firm.

A new, single-shot vaccine for dogs targets two spreading diseases. This innovation aims to make vet visits less stressful and close critical health gaps.

The fast-food giant is refinancing its debt at a much higher interest rate. Is this a savvy move to optimize its balance sheet or a costly sign of trouble?

Amid new Ebola fears, one biotech's rapid C1 platform promises 15-day biologics, eyeing a $25B market beyond just pandemic response. But can it deliver?

The collateral management firm appoints a new CPO and promotes key execs, signaling a foundational shift to build autonomous AI-native products.

With the 2026 World Cup looming, Men in Blazers partners with NFQ Technologies to build a central digital hub, aiming to turn fleeting attention into lasting loyalty.

Beyond the hype, a new report reveals a 4.8% CAGR for sports merchandise. The real story is the operational pivot to digital-first supply chains.